Lantheus Holdings, Inc. (NASDAQ:LNTH) Sees Large Decrease in Short Interest

Lantheus Holdings, Inc. (NASDAQ:LNTH) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 6,340,000 shares, a decline of 13.3% from the February 13th total of 7,310,000 shares. Based on an average daily volume of 902,000 shares, the days-to-cover ratio is presently 7.0 days. Approximately 9.5% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Stock Down 0.4 %

Shares of NASDAQ:LNTH traded down $0.42 during trading on Thursday, hitting $102.86. 68,758 shares of the stock traded hands, compared to its average volume of 932,157. The company has a fifty day moving average price of $92.54 and a two-hundred day moving average price of $96.68. Lantheus has a 52-week low of $57.78 and a 52-week high of $126.89. The company has a market cap of $7.04 billion, a price-to-earnings ratio of 17.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities research analysts predict that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its stake in Lantheus by 16.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,184 shares of the medical equipment provider’s stock worth $374,000 after purchasing an additional 576 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Lantheus during the 4th quarter worth approximately $13,081,000. Mackenzie Financial Corp grew its stake in shares of Lantheus by 4,907.1% in the fourth quarter. Mackenzie Financial Corp now owns 217,056 shares of the medical equipment provider’s stock valued at $19,418,000 after buying an additional 212,721 shares in the last quarter. Peak Retirement Planning Inc. acquired a new position in Lantheus in the 4th quarter valued at about $917,000. Finally, Woodline Partners LP grew its holdings in shares of Lantheus by 2.7% in the fourth quarter. Woodline Partners LP now owns 88,018 shares of the medical equipment provider’s stock valued at $7,874,000 after purchasing an additional 2,340 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.